Keeping You Updated
Here is a selection of recent PharmaVentures press releases...
Good deal for Merck and Schering-Plough?
Merck & Co and Schering-Plough have announced that they are to merge in a deal worth US$41.1 B. It's a deal that has been long speculated because of their existing marketing relationships over Zetia® and Vytorin® and the opportunity of potential cost savings. The combined company will generate sales of US$47 B.
Pfizer - Wyeth: Good Deal – Bad Deal?
If Pfizer and Wyeth merge to create a $60 billion company, will it be a good deal or a bad deal? Fintan Walton, PhD, CEO of PharmaVentures, says, ‘This is potentially a bad deal for both companies.'
Determining Valuations in Challenging Times
In today's financial climate, the survival of smaller companies is often dependent on their ability to do deals successfully with larger pharmaceutical companies.
Major New Report Highlights Growing Importance of IP Strategies and Competition Law in the Pharmaceuticals Industry
PharmaVentures announced today the publication of the report ‘Competition Law and Intellectual Property Strategy in the Pharmaceuticals Sector’, written by Richard Eccles and Gerry Kamstra, partners in the leading international law firm, Bird & Bird